Cancer Genetics, NovellusDx Sign Merger Agreement

Sep 18, 2018

|

NEW YORK (GenomeWeb) — Cancer Genetics (CGI) and NovellusDx announced today that they have agreed to merge.

The transaction will combine CGI's portfolio of cancer tests and laboratory service offerings with NovellusDx's next-generation sequencing and machine-learning technologies for cancer treatment response prediction.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Cancer Genetics, NovellusDx Sign Merger Agreement

To read the full story....

Breaking News

Rhinostics Licenses Procter & Gamble Nasal Swab for COVID-19 Testing

FIND, Unitaid Ink First Agreement to Enable COVID-19 Antigen Tests at $2.50 Apiece

Oppenheimer Initiates Coverage of DermTech With Outperform Rating

Invitae Prices $400M Common Stock Offering

Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

In Brief This Week: Myriad Genetics, Precipio, LumiraDx, Guardant Health, and More

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

President Biden Announces Plan to Expand SARS-CoV-2 Testing, Increase Capacity

Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

Molzym, Fraunhofer Developing Rapid Direct-From-Sample Sepsis Diagnostic Platform and Test

Invitae Prices $400M Common Stock Offering

NASA Looking to Spin Out Breath Analysis Platform for Use in Diagnostics Applications

Sponsorships